



Via Express Mail No.: EV 582 626 013 US Mailing Date: September 21, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Saxon et al.	Docket No.:	39754-0672A
Serial No.:	09/847,208	Group Art Unit:	1644
Filing Date:	May 1, 2001	Examiner:	Phuong N. Huynh
For:	FUSION MOLECULES AND TREATMENT OF IgE-MEDIATED ALLERGIC DISEASES		

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form Supplemental PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

09/26/2005 MAHMED1 00000056 081641 09847208

01 FC:1806 180.00 DA

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☒ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.


☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39754-0672A)**.

Respectfully submitted,

Dated: September 21, 2005

By: Leslie Mooi
Leslie Mooi (Reg. No. 37,047)

HELLER EHRMAN LLP (Customer No. 25213)
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000 / Facsimile: (650) 324-0638
Customer No. 25213
SV 2154502 v1



Form PTO-1449 INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i>	Attorney's Docket No. 39754-0672A	Application Serial No. 09/847,208
	Applicant(s) ANDREW SAXON et al.	
	Filing Date: May 1, 2001	Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	4.	12-19-1996	WO 96/40789	PCT	C07K	16/46		

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	1.	Harrison, L.C. and Hafler, D.A., "Antigen-Specific Therapy for Autoimmune Disease," Current Opinion in Immunology, Vol. 12, pp 704-711, 2000.
	2.	Kaplan, A.P., "Urticaria and Angioedema," Inflammation: Basic Principles and Clinical Correlates, (Gallin and Snyderman eds.), 3 rd Edition, Lippincott & Wilkins, Philadelphia, 1999, pp. 915-928.
	3.	McDevitt, H., "Specific Antigen Vaccination to Treat Autoimmune Disease," PNAS, Vol. 101:(2), pp 14627-14630 (October 5, 2004).
	4.	Pivnyuk, V.I. et al., "Human Low-Affinity IgE Receptor: cDNA from Cell Line 1B and Its Expression in Peripheral Blood Cells," Molecular Biology, Vol. 28:(4), Part 2, pp 549-552 (1994).
	5.	Tisch, R. et al., "Antigen-Specific Mediated Suppression of β Cell Autoimmunity by Plasmid DNA Vaccination," The Journal of Immunology, Vol. 166, pp 2122-2132 (2001).
	6.	Warren, K.G., et al, "Fine Specificity of the Antibody Response to Myelin Basic Protein in the Central Nervous System in Multiple Sclerosis: The Minimal B-Cell Epitope and a Model of its Features", Proc. Natl. Acad. Sci. USA, Vol. 92, pp 11061-11065, (November 1995).
	7.	Warren, K. G., "Increased Synthetic Peptide Specificity of Tissue-CSF Bound Anti-MBP in Multiple Sclerosis", Journal of Neuroimmunology, Vol. 43, pp 87-96, (1993).
	8.	Warren, K. G., "Synthetic Peptide Specificity of Anti-Myelin Basic Protein from Multiple Sclerosis Cerebrospinal Fluid", Journal of Neuroimmunology, Vol. 39, pp 81-90, (1992).
	9.	Warren, K.G., et al, "Tolerance Induction to Myelin Basic Protein by Intravenous Synthetic Peptides Containing Epitope P ₈₅ VVHFFKNIVTP ₉₆ in Chronic Progressive Multiple Sclerosis", Journal of Neurological Sciences, Vol. 152, pp 31-38, (1997).
	10.	Weiner, H. L., "Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis", Science, Vol. 259, pp 1321-1324, (February 26, 1993).

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2154502 v1	